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ABSTRACT 
A versatile (S)-3-(hydroxymethyl)butane-1,2,4-triol building block has been synthesized starting from D-isoascorbic 
acid, a common food preservative.  The key transformation in this approach was the introduction of branching 
through a high yield and fully regioselective epoxide opening.  This flexible synthon has been elaborated to a new 
class of (dihydro)-N-homo(phyto)ceramides. 
The development and availability of reliable and 
efficient methods for the construction of chiral building 
blocks are crucial for the synthesis of many 
pharmaceutical agents and complex natural products.  
These chiral building blocks can be derived from the 
chiral pool or by chemical/enzymatic means from achiral 
or racemic starting material.  
(S)-3-(Hydroxymethyl)butane-1,2,4-triol is a flexible, 
multivalent, scaffold with defined stereochemical features 
which can be exploited by judicious selection of 
appropriate protecting groups.  Some examples of the 
synthetic potential of this intermediate are summarized in 
Figure 1.  Indeed, sugar derivatives (S,S)-4-(hydroxy-
methyl)pyrrolidine-3-ol,1 the enantiomer of the common 
precursor of second-generation purine phosphorylase 
inhibitors2 and oxetanocin A, a known antibacterial, 
                                                     
1 (a) Tyler, P. C; Clinch, K. PCT Int. Appl. WO 2005033076, 2005. 
(b) Karlsson, S.; Hogberg, H.-E. Tetrahedron: Asymmetry 2001, 12, 
1977-1982. 
2 (a) Kotian, P. L.; Chand, P. Tetrahedron Lett. 2005, 46, 3327-3330. 
(b) Makino, K.; Ichikawa, Y. Tetrahedron Lett. 1998, 39, 8245-8248. (c) 
Evans, G. B.; Furneaux, R. H.; Lewandowicz, A.; Schramm, V. L.; 
Tyler, P. C. J. Med. Chem. 2003, 46, 5271-5276. 
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antitumoral and antiviral natural product,3 are readily 
accessible through a limited number of steps (A).  
Moreover, ceramide analogues with an inversed amide 
functionality (B) could provide useful biochemical tools 
for assessment of ceramide interaction with a myriad of 
clinically relevant enzymes.  Finally, simple elaboration 
of the other primary alcohol (C4-OH) to the amide part 
(C) gives access to D-threo-PDMP homologues4 (D-
threo-1-phenyl-2-amino decanoyl-3-
morpholinopropanol), an inhibitior of glucosyl ceramide 
synthase which is a potential target in the treatment of 
cancer.5 
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Figure 1. Synthetic potential of key intermediate (S)-3-
(hydroxymethyl) butane-1,2,4-triol: A) (aza)sugar derivatives; 
B) ceramides and phytoceramides with an iversed amide 
functionality; C) PDMP homologues; D) N-
(dihydro)homo(phyto)ceramides. 
 
Here, we wish to demonstrate the usefulness of the (S)-
3-(hydroxymethyl)butane-1,2,4-triol scaffold in preparing 
a novel class of homoceramide analogues (Figure 1; D), 
which contain an additional methylene group between the 
                                                     
3 Selected examples: (a) Ichikawa, E.; Yamamura, S.; Kato, K. 
Tetrahedron Lett. 1999, 40, 7285-7388. (b) Kikuchi, Y.; Kurata, H.; 
Shigeru, N.; Yamamura, S. Tetrahedron Lett. 1997, 38, 4795-4798. (c) 
Gumina, G.; Chu, C. K. Org. Lett. 2002, 4, 1147-1149. (d) Nishiyama, 
S.; Yamamura, S.; Kato, K.; Takita, T. Tetrahedron Lett. 1988, 29, 
4743-4746. 
4 Abe, A.; Wild, S. R.; Lee, L.; Shayman, J. A. Curr. Drug Metab. 
2001, 2, 331-338. 
5 (a) Radin, N. S. Bioorg. Med. Chem. 2003, 11, 2123-2142. (b) 
Reynolds, C. P.; Maurer, B. J.; Kolesnick, R. N. Cancer Lett. 2004, 206, 
169-180.  
N-acyl chain and C2 (Figure 2; 2-4).  Interestingly, our 
procedure seemed also convenient for the synthesis of N-
homophytoceramide (5), which can serve as key 
intermediate for the synthesis of -galactosyl-N-
homoceramide.  This latter compound represents a 
homologue of -galactosylceramide, a potentially useful 
agent for the treatment of autoimmune diseases.6 
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Figure 2. General stuctures of O1-homoceramides (1) and N-
(dihydro)homo(phyto)ceramides (2-5). 
 
Homologation is a classical tool in medicinal chemistry 
to alter biological properties of endogenous compounds.  
Salbutamol, for instance, a widely7 used bronchodilator 
with agonistic properties for 2-receptors, consists of a 4-
hydroxy-3-hydroxymethylphenyl moiety instead of the 
catechol ring, which is present in (nor)adrenaline. 
Recently, our group reported an expedient route for the 
synthesis of D-erythro-O1-homoceramides8 (Figure 2; 1). 
An alternative synthetic procedure for this class of non-
natural ceramide analogues was later proposed by Ogino 
and coworkers.9  The authors found that several 
representatives exhibited considerable apoptotic 
activities.  Recently, Schmidt and coworkers10 presented 
the synthesis of O1-homosphingosine-phosphonate 
starting from D-galactose. 
                                                     
6 Representative reviews: (a) Van Kaer, L. Nat. Immunol. 2005, 5, 31-
42. (b) Yamamura, T.; Miyamoto, K.; Illes, Z.; Pal, E.; Araki, M.; 
Miyake, S. Curr. Top. Med. Chem. 2004, 4, 561-567. 
7 Salbutamol is the representative for treatment of asthma and chronic 
obstructive pulmonary disease (COPD) in the WHO Essential Medicines 
Library (EMLib); Web site: http://mednet3.who.int/EMLib. 
8 De Jonghe, S.; Lamote, I.; Venkataraman, K.; Boldin, S. A.; 
Hillaert, U.; Rozenski, J.; Hendrix, C.; Busson, R.; De Keukeleire, D.; 
Van Calenbergh, S.; Futerman, A. H.; Herdewijn, P. J. Org. Chem. 
2002, 67, 988-996. 
9 (a) Shikata, K.; Niiro, H.; Azuma, H.; Tachibana, T.; Ogino, K. 
Bioorg. Med. Chem. Lett. 2003, 13, 613-616. (b) Shikata, K.; Niiro, H.; 
Azuma, H.; Ogino, K.; Tachibana, T. Bioorg. Med. Chem. 2003, 11, 
2723-2728. 
10 Tarnowski, A.; Retz, O.; Bar, T.; Schmidt, R. R. Eur. J. Org. Chem. 
2005, 6, 1129-1141. 
Epoxide synthon 6 (Scheme 1), prepared from D-
isoascorbic acid as previously described,11 provided the 
stereochemical and structural features required for our 
synthetic approach.  Since epoxide opening is often 
hampered by regioselectivity issues involving the use of 
hazardous cyanide1b or additional synthetic steps 
implicated in allylic transformations3b, we opted to use 
1,3-dithiane12 to introduce branching.   
 
Scheme 1. Synthesis of key intermediate 8. 
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Hence, tritylation followed by reduction of the ester 
and subsequent epoxide opening with 2-lithio-1,3-
dithiane13 produced intermediate 1,3-diol 7 with complete 
regioselectivity (47% yield in six steps from D-
isoascorbic acid). Protection of 1,3-diol 7 with di-tert-
butylsilyl ditriflate followed by dithiane deprotection with 
MeI under alkaline conditions and final reduction of the 
unmasked aldehyde with NaBH4 gave access to 8 (75% 
from 7, 36% from D-isoascorbic acid in 9 steps), which 
represents a unique intermediate from which each of the 
primary alcohols can selectively be addressed for further 
modification. 
Access to D-ribo-N-homophytoceramide 5 is outlined 
in Schemes 2 and 3.  Mesylation of intermediate 8 
followed by azide introduction and trityl removal yielded 
alcohol 9 in good yield (83%).  Subsequent periodinane 
oxidation and addition of tetradecylmagnesium chloride 
to the thus formed aldehyde furnished protected azido-N-
homophytosphingosine 10 (40%) as a single diastereo-
meric form. 
                                                     
11 (a) Dunigan, J.; Weigel, L. O. J. Org. Chem. 1991, 56, 6225-2557. 
(b) Ikunaka, M.; Matsumoto, J.; Fujima, Y.; Hirayama, Y. Org. Process 
Res. & Dev. 1, 2002, 6, 49. (c) Ziegler, F. E.; Belema, M. J. Org. Chem. 
1994, 59, 7962. 
12 For a review on the role of 1,3-dithianes in natural product 
synthesis see: Yus, M.; Nájera, C.; Foubelo, F. Tetrahedron 2003, 59, 
6147-6212. 
13 Paquette, L. A.; Boulet, S. L. Synthesis 2002, 888-894. 
 
Scheme 2. Synthesis of azido intermediate 10. 
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Assignment of the erythro configuration was achieved 
by converting intermediate 10 to the 3,4-isopropylidene 
protected triol 11 in a two steps sequence entailing silyl 
deprotection and dioxolane formation (Scheme 3; 51%) 
and subsequent comparison of 1H NMR data with 
similarly protected natural D-ribo-azidophytosphingosine 
12.14,15   
 
Scheme 3. Synthesis of D-ribo-N-homophytoceramide 5. 
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14 (a) Compound 12 has been prepared according to literature 
procedures starting from commercially available D-ribo-phyto-
sphingosine (ref. 15) (b) Both 11 (3J3,4 = 5.57 Hz) and 12 (3J3,4 = 5.38 
Hz) exhibit a comparable vicinal coupling constant thereby indicating a 
cis-relationship of the ring substituents (standard sphingolipid 
numbering is used for clarity reasons).  
15 Schmidt, R. R.; Maier, T. Carbohydr. Res. 1998, 174, 169-179.  
Azide reduction under Staudinger conditions following 
TBDMS protection of the secondary alcohol in 10 and 
subsequent acylation of the primary amine with palmitoyl 
chloride afforded silyl protected intermediate 13 (39%).  
Final desilylation with TBAF furnished D-ribo-N-
homophytoceramide 5 (62%). 
 
Scheme 4. Synthesis of Z-alkene intermediate 15. 
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Since the presence of azides in Wittig olefination has 
led to controversial results,16 we opted to transform the 
azide to a phthalimide in a two step sequence involving 
reduction of 9 under Staudinger conditions followed by 
phthalimide protection of the thus formed primary amine, 
thereby affording intermediate 14 in good yield (Scheme 
4; 88%). 
 
Scheme 5. Access to (dihydro)-N-homoceramides 2-4. 
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16 Selected examples: (a) Nugent, T. C.; Hudlicky, T. J. Org. Chem. 
1998, 63, 510-520. (b) Timmer, M. S. M.; Verdoes, M.; Sliedregt, L. A. 
J. M.; van der Marel, G. A.; van Boom, J. H.; Overkleeft, H. S. J. Org. 
Chem. 2003, 68, 9406-9411.(c) Hudlicky, T.; Nugent, T. J. Org. Chem. 
1994, 59, 7944-7946.  
Subsequent oxidation of the primary alcohol with 
Dess-Martin periodinane yielded the intermediate 
aldehyde.  Although reaction conditions specifically 
addressed the E-isomer, Schlosser-Wittig olefination 
surprisingly only produced Z-isomer 15.  Hydrazine 
mediated phthalimide deprotection followed by acylation 
with palmitoyl chloride and silyl deprotection with TBAF 
furnished Z-N-homoceramide 2 (Scheme 5; 59%).  Photo-
induced double bond isomerisation in the presence of 
diphenyl disulfide as sensitizer produced, after two 
recrystallisations, isomerically pure E-N-homoceramide 3 
(38%).  Finally, hydrogenation of the Z-double bond in 2 
gave access to dihydro-N-homoceramide 4 (84%). 
In summary, we have reported an expedient route 
towards a versatile (S)-3-(hydroxymethyl)butane-1,2,4-
triol scaffold starting from D-ascorbic acid, a common 
food preservative.  The key transformation in this 
approach was the introduction of branching through a 
high yield and fully regioselective 2-lithio-1,3-dithiane 
epoxide opening.  Based on this flexible synthon, we 
report the first synthesis of (dihydro)-N-homoceramides 
2-4. In addition, a fully stereoselective Grignard reaction 
gave access to D-ribo-N-homophytoceramide 5, which 
will be utilised in a further study towards the elaboration 
of its -galacosyl derivative. 
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